Results 201 to 210 of about 63,989 (248)

Activated charcoal neutralization restores accurate Model for End-Stage Liver Disease and Child-Pugh scores in patients with cirrhosis on direct oral anticoagulant therapy. [PDF]

Res Pract Thromb Haemost
Habay C, Riescher Tuczkiewicz A, Ben Salah I, Trichet C, Gay J, Durand F, Rautou PE, Roux O, De Raucourt E.   +8 more
europepmc   +1 more source

OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation. [PDF]

Eur Heart J Cardiovasc Pharmacother
Galli M, Simeone B, Sciarretta S.
europepmc   +1 more source

Dose Optimization of Rivaroxaban in Elderly Chinese Patients with Non-Valvular Atrial Fibrillation: Analysis of Populations Pharmacokinetics and Exposure-Response Relationships. [PDF]

Drug Des Devel Ther
Li TY, Liu X, Tang L, Cai W, Zhang J, Su Y, Yu C, Liu BJ, Jiang LF, Liu C, Yu YX.   +10 more
europepmc   +1 more source

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

New England Journal of Medicine, 2011
Werner Hacke, Günter Breithardt, Jonathan Halperin   +2 more
exaly   +3 more sources

Rivaroxaban in Peripheral Artery Disease after Revascularization

New England Journal of Medicine, 2020
BACKGROUND Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.
Marc P Bonaca, Sonia Anand, Fabrizio Fanelli   +2 more
exaly   +2 more sources

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

New England Journal of Medicine, 2017
John W. Eikelboom, Stuart J Connolly, Jackie J Bosch   +2 more
exaly   +2 more sources

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Lancet, The, 2018
BACKGROUND Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.
Sonia Anand, Jackie J Bosch, John W. Eikelboom   +2 more
exaly   +2 more sources

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

New England Journal of Medicine, 2018
Background Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke ...
Robert Hart, Mukul Sharma, Hardi Mundl
exaly   +2 more sources